Alluvi, known as BI 4744, presents a notable breakthrough in obesity care. This dual agonist targeting both GLP-1 and GIP sites demonstrates compelling efficacy in clinical trials, potentially exceeding available GLP-1 https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/